Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05082610
Title A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hummingbird Bioscience, Inc.

triple-receptor negative breast cancer

lung non-small cell carcinoma

Advanced Solid Tumor



HMBD-002 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST